Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Unauthorized health products seized from Tokyo Beauty & Health Care in Richmond, B.C., may pose serious health risks


OTTAWA, ON, March 31, 2021 /CNW/ -

Summary

Issue
Health Canada has seized several health products?including eye drops, an eyewash and an acne gel?from Tokyo Beauty & Health Care in Richmond, British Columbia (#120, 8191 Westminster Highway), because they are unauthorized and may pose serious health risks.

According to the product labels, the products contain prescription drugs (see table below for details). Prescription drugs should be taken only under the advice and supervision of a health care professional because of the risk of interactions with other medications and side effects. Prescription drugs can only be legally sold via a prescription. 

Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, effectiveness and quality and may pose serious health risks. They may contain ingredients, additives or contaminated ingredients not listed on the label. In addition, they may lack the active ingredients Canadians would expect them to contain to help maintain and improve their health or they may contain ingredients that could interact with other medications and foods. For all of these reasons, unauthorized health products could cause serious health effects. Selling unauthorized health products in Canada is illegal.

Some of the unauthorized health products are packaged and labelled in Japanese characters. As a result, information about ingredients, usage, dosage and side effects may not be understood by all consumers.

Health Canada has previously seized unauthorized products being sold by this retailer and will continue to take action to address this illegal activity and update Canadians as needed. 

Affected products

Product

Risk

Dalacin T Gel 1%
Anti-bacterial gel for acne

Labelled (in Japanese) to contain clindamycin

Kobayashi Aibon/Eyebon Eyewash ALd
(dark green)

Eyewash

Labelled (in Japanese) to contain aminocaproic
acid

Kobayashi Aibon/Eyebon Eyewash Medicala
(black)

Eyewash

Labelled (in Japanese) to contain aminocaproic
acid

Kobayashi Aibon/Eyebon Eyewash Mild
(light green)
Eyewash

Labelled (in Japanese) to contain aminocaproic acid

Santen Sante Beauteye Contact

Eye drops

Labelled (in Japanese) to contain neostigmine
methylsulfate

Santen Sante FX Neo (silver package)

Eye drops

Labelled (in English) to contain neostigmine
methylsulfate and aminocaproic acid

Santen Sante FX Neo (blue package)

Eye drops

Labelled (in Japanese) to contain neostigmine
methylsulfate and aminocaproic acid

Santen Sante FX Vplus (gold package)

Eye drops

Labelled (in English) to contain neostigmine
methylsulfate and aminocaproic acid

Santen Sante FX Vplus (red package)

Eye drops

Labelled (in Japanese) to contain neostigmine
methylsulfate and aminocaproic acid

Santen Sante PC

Eye drops

Labelled (in Japanese) to contain neostigmine
methylsulfate

What you should do

Background
Aminocaproic acid:
This is a prescription drug ingredient used to decrease bleeding in various clinical situations. Exposure to aminocaproic acid in the eye may affect the eye itself, and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, vision changes, headache, dizziness, nausea, muscle weakness and skin rash.

Clindamycin: In topical format (i.e., applied to the skin), this is a prescription antibiotic approved in Canada to treat bacterial infections, including those associated with acne. The product should not be used in individuals with a history of ulcerative colitis (inflamed bowel) or a history of inflamed bowel associated with antibiotic use (antibiotic-associated colitis). Side effects may include dry or scaly skin, peeling skin, a stinging or burning feeling on the skin, eye pain, itching, hives, redness and gastrointestinal symptoms (such as indigestion and gas). Safety and effectiveness in children under the age of 12 has not been established.

Neostigmine methylsulfate: There are no approved eye drops containing neostigmine methylsulfate on the Canadian market. In the past, drugs similar to neostigmine were used to treat glaucoma. These medications are no longer widely used because of the significant number of potential eye-related side effects, including blurred distance vision, frontal headaches, twitching lids, red eyes, cataracts, allergic reactions, iris cysts, retinal detachment and the potential for causing a specific type of glaucoma attack. In addition, absorption into the nose via the tear duct may cause serious cardiac and respiratory side effects.

Images:
For photos of these products, please visit the online safety alert.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 10:00
Summary Products: Magnesium Bis-Glycinate Powder 250 (Berry Hibiscus) and Magnesium Bis-Glycinate Powder 250 (Rose Hip Dragonfruit) Issue: Affected lots were packaged with a scoop that is nearly twice the size it should be, which may lead users to...

at 06:50
New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with...

at 05:57
Delic Holdings Inc. ("DELIC" or the "Company") , a psychedelic wellness-focused company, announces that the Company is not aware of any material undisclosed information and wishes to make the following statements regarding recent sponsored news and...

7 mai 2021
The global moist wound dressings market is set to grow by USD 1.25 billion during 2021-2025, registering a CAGR of almost 6%. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the...

7 mai 2021
Goldenway International Trade Co., Ltd. is recalling Golden Mushroom brand Enoki Mushroom from the marketplace due to possible Listeria monocytogenes contamination. Consumers should not consume the recalled product described below. The following...

7 mai 2021
The hemodialysis equipment market is expected to grow by USD 3.57 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the hemodialysis equipment market in optimistic, probable,...



News published on 31 march 2021 at 16:45 and distributed by: